All subtypes except basal-like BC responded favorably to treatment with paclitaxel, anthracyclines, and alkylating agents as well as HER2-targeting monoclonal antibodies and endocrine therapy (Kennecke et al., 2010; Kim et al., 2020). This evidence concerns the gene ERBB2 and breast cancer.